Holen Sie sich die Stockscreener-App
7.87
1.70%
0.15
Sagimet Biosciences Inc Aktie (SGMT) Neueste Nachrichten
Does Sagimet Biosciences Inc. (SGMT) have the potential to rally 241.77% as Wall Street analysts expect? - MSN
Sagimet Biosciences Inc. (SGMT) is a Great Momentum Stock: Should You Buy? - sharewise.com
Does Sagimet Biosciences Inc. (SGMT) Have the Potential to Rally 241.77% as Wall Street Analysts Expect? - Yahoo Finance
Sagimet Biosciences shares jump 30% on acne trial expansion plans - MSN
Sagimet Biosciences Price Target Raised to $49.00/Share From $28.00 by Canaccord Genuity - Moomoo
symbol__ Stock Quote Price and Forecast - CNN
Sagimet Biosciences | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plansmoomoo - Moomoo
Wedbush Maintains Sagimet Biosciences(SGMT.US) With Buy Rating, Maintains Target Price $28 - Moomoo
Oppenheimer Adjusts Price Target on Sagimet Biosciences to $33 From $28, Maintains Outperform Rating - marketscreener.com
Sagimet Therapeutics: Buy Rating Reiterated on Denifanstat’s First-Line Acne Potential; $28 Price Target Unchanged - TipRanks
Oppenheimer Maintains Sagimet Biosciences(SGMT.US) With Buy Rating, Raises Target Price to $33 - Moomoo
Sagimet Biosciences Targets Acne, Plans U.S. Phase III for Denifanstat After $175M Raise - MarketBeat
Guggenheim Lowers Sagimet Biosciences (NASDAQ:SGMT) Price Target to $25.00 - MarketBeat
Why Is Sagimet Biosciences Stock Trading Higher On Monday? - Sahm
Sagimet Biosciences offers 29.17 million shares of series A common stockSEC filing - marketscreener.com
Sagimet Biosciences Announces Major Equity Offering for Pipeline - TipRanks
Sagimet Biosciences | 424B5: Prospectus - Moomoo
Sagimet Biosciences | 8-K: Current report - Moomoo
Sagimet Biosciences (NASDAQ: SGMT) prices $164.5M equity raise to fund trials - Stock Titan
Sagimet Biosciences (NASDAQ: SGMT) raises $175M to fund Phase 3 denifanstat - Stock Titan
SGMT - Finviz
SGMT Stock Price, Quote & Chart | SAGIMET BIOSCIENCES INC-A (NASDAQ:SGMT) - ChartMill
Sagimet Biosciences rockets 30% on pricing $175M equity offering - MSN
Sagimet prices $175M stock offering to fund acne drug trials By Investing.com - Investing.com India
Sagimet Biosciences Stock Soars After Positive Data For Experimental Drug In Acne Study - MSN
Sagimet Stock Surges as $175 Million Raise Sharpens Acne Drug Push - TechStock²
Sagimet prices $175M stock offering to fund acne drug trials - Investing.com UK
Why Sagimet Biosciences Stock Is Soaring Today - AOL.com
Oppenheimer raises Sagimet stock price target on acne focus - Investing.com UK
Oppenheimer raises Sagimet stock price target on acne focus By Investing.com - Investing.com South Africa
Sagimet Biosciences Shares Jump 30% on Acne Trial Expansion Plans - Yahoo Finance
SGMT stock surged 40% and breached 200-DMA for the first time in nearly 3 months – what’s got retail buzzing? - MSN
Sagimet Biosciences surges as $175M equity financing and acne-focused pipeline update reset the runway narrative - Quiver Quantitative
SGMT Stock Surged 40% And Breached 200-DMA For The First Time In Nearly 3 Months – What’s Got Retail Buzzing? - Stocktwits
Sagimet Biosciences Advances Denifanstat and TVB-3567 as Novel FASN Inhibitors for Moderate to Severe Acne and MASH Treatment 23469 - Minichart
Sagimet Biosciences Advances Denifanstat and TVB-3567 as Novel FASN Inhibitors for Moderate to Severe Acne and MASH Treatment (2026 Update) - Minichart
Sagimet Biosciences (SGMT) Jumps As MASH Data Buzz Builds - StocksToTrade
Sagimet Biosciences to Fund Phase 3 Acne Trial in US With $175 Million Offering - marketscreener.com
Sagimet Biosciences SGMT Gains Attention On MASH Data - timothysykes.com
Sagimet plans U.S. Phase 3 acne trial in second half of 2026 - Investing.com UK
Morning Market Movers: SGMT, CMPX, ORKA, MANE See Big Swings - RTTNews
Sagimet Updates Investor Presentation After Key Clinical Milestones - TipRanks
Sagimet Highlights Pipeline Progress and Strategic Corporate Developments - TipRanks
Sagimet Biosciences stock surges 30% on acne trial plans By Investing.com - Investing.com South Africa
Sagimet plans U.S. Phase 3 acne trial in second half of 2026 By Investing.com - Investing.com South Africa
Sagimet Biosciences stock surges 30% on acne trial plans - Investing.com
Sagimet Biosciences to advance denifanstat to Phase 3 trial for U.S. acne market after China data - Traders Union
Sagimet Biosciences (SGMT) furnishes updated investor presentation via Form 8-K - Stock Titan
Sagimet Biosciences Inc. Prices Underwritten Offering of 29.2 Million Shares at $6.00 Each, Expected to Raise $175 Million - Quiver Quantitative
Sagimet raises $175M, says cash now funds acne programs through 2028 - Stock Titan
Sagimet Biosciences Announces Pricing of $175.0 Million Underwritten Offering of Series A Common Stock - GlobeNewswire
0.78%
3.01%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):